SEARCH

SEARCH BY CITATION

References

  • 1
    Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 34154.
  • 2
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 12737.
  • 3
    Schiller JH, Harrington D, Belani CP et al . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 928.
  • 4
    Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 295870.
  • 5
    Fukuoka M, Yano S, Giaccone G et al . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 223746.
  • 6
    Kris MG, Natale RB, Herbst RS et al . Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 214958.
  • 7
    Miller VA, Kris MG, Shah N et al . Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 11039.
  • 8
    Lynch TJ, Bell DW, Sordella R et al . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 212939.
  • 9
    Paez JG, Janne PA, Lee JC et al . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497500.
  • 10
    Pao W, Miller V, Zakowski M et al . EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13 30611.
  • 11
    Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006; 11: 1908.
  • 12
    Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 891923.
  • 13
    Matsuo K, Ito H, Yatabe Y et al . Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 2006; 98: 96101.
  • 14
    Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 11637.
  • 15
    Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20: 1496510.
  • 16
    Ji H, Li D, Chen L et al . The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006; 9: 48595.
  • 17
    Inoue A, Suzuki T, Fukuhara T et al . Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 33406.
  • 18
    Han SW, Kim TY, Hwang PG et al . Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493501.
  • 19
    Mitsudomi T, Kosaka T, Endoh H et al . Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 251320.
  • 20
    Takano T, Ohe Y, Sakamoto H et al . Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 682937.
  • 21
    Bell DW, Lynch TJ, Haserlat SM et al . Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 808192.
  • 22
    Eberhard DA, Johnson BE, Amler LC et al . Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 59009.
  • 23
    Riely GJ, Pao W, Pham D et al . Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 83944.
  • 24
    Jackman DM, Yeap BY, Sequist LV et al . Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 390814.
  • 25
    Greulich H, Chen T-H, Feng W et al . Oncogenic transformation by inhibitor-sensitive and resistant EGFR mutations. PLoS Med 2005; 2: e313.
  • 26
    Carey KD, Garton AJ, Romero MS et al . Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006; 66: 816371.
  • 27
    Mulloy R, Ferrand A, Kim Y et al . Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007; 67: 232530.
  • 28
    Cappuzzo F, Hirsch FR, Rossi E et al . Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 64355.
  • 29
    Tsao MS, Sakurada A, Cutz JC et al . Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 13344.
  • 30
    Han SW, Kim TY, Jeon YK et al . Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006; 12: 253844.
  • 31
    Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006; 354: 5268.
  • 32
    Slebos RJ, Kibbelaar RE, Dalesio O et al . K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 5615.
  • 33
    Shigematsu H, Lin L, Takahashi T et al . Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 33946.
  • 34
    Pao W, Wang TY, Riely GJ et al . KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
  • 35
    Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T. PTEN and PIK3A expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 2006; 1: 62934.
  • 36
    Miller VA, Zakowski M, Riely GJ et al . EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. J Clin Oncol (Meeting Abstracts) 2006; 24: 7003.
  • 37
    Shigematsu H, Takahashi T, Nomura M et al . Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 16426.
  • 38
    Wang SE, Narasanna A, Perez-Torres M et al . HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 2538.
  • 39
    Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006; 354: 261921.
  • 40
    Cappuzzo F, Varella-Garcia M, Shigematsu H et al . Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005; 23: 500718.
  • 41
    Cappuzzo F, Toschi L, Domenichini I et al . HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 2005; 93: 133440.
  • 42
    Brose MS, Volpe P, Feldman M et al . BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 69977000.
  • 43
    Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002; 62: 70013.
  • 44
    Sasaki H, Kawano O, Endo K et al . Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 2006; 133: 2036.
  • 45
    Ji H, Wang Z, Perera SA et al . Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007; 67: 49339.
  • 46
    Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 9219.
  • 47
    Soda M, Choi YL, Enomoto M et al . Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 5616.
  • 48
    Marks JL, McLellan MD, Zakowski MF et al . Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2007; 2: e426.
  • 49
    Kobayashi S, Boggon TJ, Dayaram T et al . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 78692.
  • 50
    Pao W, Miller VA, Politi KA et al . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib Is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
  • 51
    Balak MN, Gong Y, Riely GJ et al . Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12: 6494501.
  • 52
    Kosaka T, Yatabe Y, Endoh H et al . Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006; 12: 57649.
  • 53
    Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003; 278: 15 43540.
  • 54
    Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 2005; 352: 2136.
  • 55
    Bell DW, Gore I, Okimoto RA et al . Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005; 37: 131516.
  • 56
    Vikis H, Sato M, James M et al . EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007; 67: 466570.
  • 57
    Inukai M, Toyooka S, Ito S et al . Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006; 66: 78548.
  • 58
    Engelman JA, Mukohara T, Zejnullahu K et al . Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006; 116: 2695706.
  • 59
    Shah NP, Nicoll JM, Nagar B et al . Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 11725.
  • 60
    Carter TA, Wodicka LM, Shah NP et al . Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102: 11 01116.
  • 61
    Engelman JA, Zejnullahu K, Mitsudomi T et al . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 103943.
  • 62
    Shibata T, Uryu S, Kokubu A et al . Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 2005; 11: 617785.
  • 63
    Ando M, Okamoto I, Yamamoto N et al . Predicitive factors for interstitial lung disease, anti-tumor response and survival in non-smal cell lung cancer patients treated with gefiitinib. J Clin Oncol 2006; 24: 254956.
  • 64
    Cappuzzo F, Ligorio C, Janne PA et al . Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007; 25: 224855.
  • 65
    Satouchi M, Negoro S, Funada Y et al . Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer 2007; 96: 11916.
  • 66
    Yoshida K, Yatabe Y, Park JY et al . Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2007; 2: 228.
  • 67
    Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 2007; 96: 85763.
  • 68
    Asahina H, Yamazaki K, Kinoshita I et al . A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006; 95: 9981004.
  • 69
    Sunaga N, Tomizawa Y, Yanagitani N et al . Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007; 56: 3839.
  • 70
    Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med 2007; 13: 6757.